Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTOXLG)

Drug Name

PPI-461 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis C virus Non-structural 5A (HCV NS5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daclatasvir	DMSFK9V	Hepatitis C virus infection	1E51.1	Approved	[3]
Glecaprevir; pibrentasvir	DMF6Z5T	Hepatitis C virus infection	1E51.1	Approved	[4]
ABT-267	DMNQ869	Hepatitis C virus infection	1E51.1	Phase 3	[5]
MK-8742	DMK301H	Hepatitis C virus infection	1E51.1	Phase 3	[6]
Ravidasvir	DM1LFUN	Hepatitis C	1E51	Phase 2/3	[7]
GS-5885	DMSL3DX	Hepatitis C virus infection	1E51.1	Phase 2	[8]
PPI-668	DM4EHVB	Hepatitis C virus infection	1E51.1	Phase 2	[2]
ACH-3102	DM0RPY5	Hepatitis C virus infection	1E51.1	Phase 2	[2]
AZD-2836	DMT2FAP	Hepatitis C virus infection	1E51.1	Phase 1/2	[9]
BMS-824383	DMPQ5XC	Hepatitis C virus infection	1E51.1	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus Non-structural 5A (HCV NS5A)	TTCJ2X8	POLG_HCV1	Modulator	[2]

------------------------------------------------------------------------------------

References

1	2011 Pipeline of Presidio.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	2011 Pipeline of Bristol-Myers Squibb.
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
6	Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
7	Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
8	Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
9	TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.